NA
AMPH icon

Navellier & Associates’s Amphastar Pharmaceuticals AMPH Stock Holding History

Navellier & Associates’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,591
Closed -$1.52M – 339
2024
Q1 		$1.52M Buy
34,591
+26,864
+348% +$1.39M 0.19% 123
2023
Q4 		$478K Buy
+7,727
New +$406K 0.07% 235
2023
Q1 		– Sell
-13,155
Closed -$369K – 273
2022
Q4 		$369K Sell
13,155
-9,436
-42% -$274K 0.08% 199
2022
Q3 		$635K Sell
22,591
-178
-0.8% -$5.81K 0.14% 141
2022
Q2 		$792K Buy
22,769
+31
+0.1% +$1.11K 0.17% 134
2022
Q1 		$816K Buy
+22,738
New +$645K 0.14% 139

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Navellier & Associates's AMPH Position: Q2 2024 in Review

Navellier & Associates sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2024, closing a stake of 34,591 shares — an estimated $1.52M sold.

Navellier & Associates first reported a position in AMPH in Q1 2022 and held it in 6 quarters. The position peaked at $1.52M in Q1 2024. 269 funds tracked by Wall St. Rank hold AMPH as of Q2 2024.

  • Navellier & Associates reported no remaining Amphastar Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Navellier & Associates sold 34,591 Amphastar Pharmaceuticals shares in Q2 2024, an estimated $1.52M.
  • Navellier & Associates first reported a position in Amphastar Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Navellier & Associates's Amphastar Pharmaceuticals position peaked at $1.52M in Q1 2024.
  • 269 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2024.

Based on Navellier & Associates's 13F filing for Q2 2024, filed 8 Aug 2024.